Loading...
Haemonetics Corporation
HAE•NYSE
Healthcare
Medical - Instruments & Supplies
$75.20
$0.94(1.27%)
Haemonetics Corporation (HAE) Financial Performance & Income Statement Overview
Review Haemonetics Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
12.01%
↑ 12.01%
Operating Income Growth
5.67%
↑ 5.67%
Net Income Growth
1.87%
↑ 1.87%
Operating Cash Flow Growth
-33.44%
↓ 33.44%
Operating Margin
16.30%
↑ 16.30%
Gross Margin
55.04%
↑ 55.04%
Net Profit Margin
12.32%
↑ 12.32%
ROE
18.41%
↑ 18.41%
ROIC
11.84%
↑ 11.84%
Haemonetics Corporation (HAE) Income Statement & Financial Overview
Review Haemonetics Corporation's (HAE) income statement with detailed quarterly and annual figures.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $348.54M | $345.51M | $336.17M | $343.29M |
| Cost of Revenue | $155.00M | $158.07M | $169.35M | $171.69M |
| Gross Profit | $193.55M | $187.44M | $166.82M | $171.60M |
| Gross Profit Ratio | $0.56 | $0.54 | $0.50 | $0.50 |
| R&D Expenses | $15.83M | $16.53M | $14.46M | $13.99M |
| SG&A Expenses | $106.46M | $106.95M | $107.98M | $106.44M |
| Operating Expenses | $134.52M | $135.74M | $122.44M | $120.44M |
| Total Costs & Expenses | $289.51M | $293.81M | $291.79M | $292.13M |
| Interest Income | $0.00 | $0.00 | $6.96M | $0.00 |
| Interest Expense | $9.11M | $6.99M | $6.96M | $6.53M |
| Depreciation & Amortization | $29.02M | $0.00 | $29.14M | $27.64M |
| EBITDA | $90.03M | $51.70M | $73.51M | $78.80M |
| EBITDA Ratio | $0.26 | $0.15 | $0.22 | $0.23 |
| Operating Income | $59.03M | $51.70M | $44.38M | $51.16M |
| Operating Income Ratio | $0.17 | $0.15 | $0.13 | $0.15 |
| Other Income/Expenses (Net) | -$9.11M | -$6.99M | $6.96M | -$27.75M |
| Income Before Tax | $49.92M | $44.70M | $46.71M | $23.41M |
| Income Before Tax Ratio | $0.14 | $0.13 | $0.14 | $0.07 |
| Income Tax Expense | $12.42M | $10.87M | $8.34M | $3.05M |
| Net Income | $37.49M | $33.83M | $38.37M | $20.37M |
| Net Income Ratio | $0.11 | $0.10 | $0.11 | $0.06 |
| EPS | $0.75 | $0.66 | $0.75 | $0.40 |
| Diluted EPS | $0.74 | $0.66 | $0.74 | $0.40 |
| Weighted Avg Shares Outstanding | $50.29M | $50.90M | $50.94M | $50.79M |
| Weighted Avg Shares Outstanding (Diluted) | $50.64M | $51.24M | $51.56M | $51.41M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan